Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Innovent Reports Positive Data from GLP-1R/GCGR Agonist in Weight Loss Trial

publication date: May 11, 2023

Suzhou Innovent Biologics reported that a high dose (9 mg) of mazdutide produced a mean weight loss of 15.4% in obese China patients who were treated for 24 weeks in a Phase II trial. Innovent acquired China rights to the drug, a dual GLP-1R and GCGR agonist, from its US partner, Lilly. Mazdutide is a mammalian oxyntomodulin (OXM) analogue designed to treat type 2 diabetes. It promotes insulin secretion, lowers blood glucose and reduces body weight, while it may also increase energy expenditure and improve hepatic fat metabolism by activating the glucagon receptor. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital